Fermer le menu


Member of Lyonbiopole


Geneuro is a product development company, developing a pioneering approach for the therapy of diseases associated with human endogeneous retrovirus expression, with a primary focus on nervous system diseases. Geneuro anticipates the first clinical trial of its monoclonal antibody early 2011 in multiple sclerosis and also carries out extensive preclinical research in other diseases such as ALS and schizophrenia. Geneuro breakthrough innovation targets the envelope protein of human endegeneous retroviruses. Its lead product, a monoclonal antibody, acts agasint key processes fueling neurodegeneration, the key unmet medical need in Multiple sclerosis. Geneuro is driven by entrepreneurial spirit and supported by a well established network of worldwide leading industrial and academic partners.


Strategic application domain: Human Medicine

Application market: Neurology & Mental Health Disorders

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide

Created on feb. 18th, 2009 - 9 employees



60 avenue de Rockefeller 69008 Lyon



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.